Observational Study of Talimogene Laherparepvec use for Melanoma in Clinical Practice in the United States (COSMUS-1)

• DOI: 10.2217/mmt-2019-0012
• Publication Date: 2019-07-03T14:28:54Z
• Authors: Matthew C Perez; Jonathan S Zager; Thomas Amatruda; Robert Conry; Charlotte Ariyan; Anupam Desai; John M Kirkwood; Sheryl Treichel; David Cohan; Leon Raskin
• Keywords: Clinical Practice; Complete response; Target lesion

Talimogene laherparepvec (T-VEC) is an intralesional treatment for unresectable cutaneous, subcutaneous and nodal melanoma. COSMUS-1 was conducted to examine how T-VEC used in US clinical practice.A chart review at seven centers, with 78 patients screened 76 eligible.Patients began between October 2015 December 2016. Median follow-up 9.4 months. Twenty percent of (n = 15) completed no remaining injectable lesions or pathologic complete response. Flu-like symptoms were the most commonly reported adverse events 8; 10.5%), followed by lesion ulceration 4; 5.3%). No herpetic infections reported.T-VEC well tolerated showed utility.